Stereochemistry | ACHIRAL |
Molecular Formula | C5H15NO7P2 |
Molecular Weight | 263.1226 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O
InChI
InChIKey=UGEPSJNLORCRBO-UHFFFAOYSA-N
InChI=1S/C5H15NO7P2/c1-6(2)4-3-5(7,14(8,9)10)15(11,12)13/h7H,3-4H2,1-2H3,(H2,8,9,10)(H2,11,12,13)
Molecular Formula | C5H15NO7P2 |
Molecular Weight | 263.1226 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Olpadronate, a nitrogenated bisphosphonate that can inhibit bone resorption. Although it shares the therapeutic and pharmacological properties of pamidronate and alendronate, it has a greater dosage amplitude, more predictable effects, and greater digestive tolerability than other bisphosphates. Clinical trials have shown that the oral olpadronate was well tolerated and effective in the treatment of Paget's disease. In addition, the drug is ongoing in phase II clinical trials in the Netherlands. This clinical trial has to assess the efficacy of the intravenous drug in decreasing the average back pain intensity from baseline.
Approval Year
PubMed
Sample Use Guides
Paget's disease: olpadronate was given orally in doses of 100 to 200 mg/day. Initial dose and/or increment of the dose during treatment were decided accordingly to the biochemical response
Olpadronate intra venous in chronic low back pain: 20 mg and 40 mg
Route of Administration:
Other